Influence of the TSH receptor gene on susceptibility to Graves' disease and Graves' ophthalmopathy.

BACKGROUND A large gene region, called GD-1, was first described by this laboratory as linked to Graves' disease (GD) and included the gene for the thyroid-stimulating hormone receptor (TSHR). Recent studies have now suggested an association of TSHR intronic polymorphisms with GD. We have taken the opportunity to examine a population of well-characterized patients with autoimmune thyroid disease (AITD) typed for an additional thyroid susceptibility gene, the immunoregulatory gene for cytotoxic T-lymphocyte antigen 4 (CTLA-4), to examine its relationship with the susceptibility to GD endowed by TSHR gene polymorphisms. METHODS We used TSHR-SNP-rs2268458, located in intron 1 of the TSHR gene, measured using standard PCR-RFLP procedures, as our marker for the TSHR gene association. We genotyped 200 patients with GD, 83 patients with Hashimoto's thyroiditis (HT), and 118 healthy controls (all female Caucasians). RESULTS The allele and genotype frequencies from GD patients, but not HT patients, were significantly different from controls. The frequency of the combined genotype (allele) CC + TC was significantly higher in GD patients versus controls, suggesting that the C-containing genotype increased the risk for GD in a dominant manner (p = 0.018, odds ratio [OR] = 1.8). When compared with CTLA-4 (A/G)(49) single-nucleotide polymorphism (SNP), we were unable to demonstrate additive risk in patients with established AITD. Further, subsetting the patients (n = 120) into those with clinically significant Graves' ophthalmopathy (GO) showed no association with the TSHR SNP. CONCLUSIONS These results demonstrated that the intronic TSHR-SNP-rs2268458 was associated with GD, but not with HT, thus indicating that the TSHR gene has the potential to increase susceptibility to GD. However, we were not able to demonstrate any additive risk with the CTLA-4 (A/G)(49) SNP, which is, therefore, an independent risk factor for AITD. This suggested that, within the limits of the study population, each of these two genes provided a small contribution to GD susceptibility and that neither was essential. In addition, there was no evidence for the TSHR gene association adding to the risk of developing GO. Direct functional analyses are now needed to help explain the mechanisms of this TSHR gene susceptibility to GD.

[1]  K. Jażdżewski,et al.  Interleukin (IL)-23 receptor is a major susceptibility gene for Graves' ophthalmopathy: the IL-23/T-helper 17 axis extends to thyroid autoimmunity. , 2008, The Journal of clinical endocrinology and metabolism.

[2]  E. Jacobson,et al.  The genetic basis of thyroid autoimmunity. , 2007, Thyroid : official journal of the American Thyroid Association.

[3]  J. Ioannidis,et al.  Cytotoxic T-lymphocyte associated antigen 4 gene polymorphisms and autoimmune thyroid disease: a meta-analysis. , 2007, The Journal of clinical endocrinology and metabolism.

[4]  N. Rajewsky,et al.  Regulation of the Germinal Center Response by MicroRNA-155 , 2007, Science.

[5]  Sergio Verjovski-Almeida,et al.  Genome mapping and expression analyses of human intronic noncoding RNAs reveal tissue-specific patterns and enrichment in genes related to regulation of transcription , 2007, Genome Biology.

[6]  J. Mattick,et al.  Non-coding RNA. , 2006, Human molecular genetics.

[7]  J. Connell,et al.  Association of the TSHR gene with Graves' disease: the first disease specific locus , 2005, European Journal of Human Genetics.

[8]  Rauf Latif,et al.  Thyrotropin receptor-associated diseases: from adenomata to Graves disease. , 2005, The Journal of clinical investigation.

[9]  K. Lindblad-Toh,et al.  Systematic discovery of regulatory motifs in human promoters and 3′ UTRs by comparison of several mammals , 2005, Nature.

[10]  Y. Tomer,et al.  Analysis of immune regulatory genes in familial and sporadic Graves' disease. , 2004, The Journal of clinical endocrinology and metabolism.

[11]  B Murphy,et al.  Analysis of the CTLA-4, CD28, and inducible costimulator (ICOS) genes in autoimmune thyroid disease , 2003, Genes and Immunity.

[12]  G. Barbesino,et al.  Common and unique susceptibility loci in Graves and Hashimoto diseases: results of whole-genome screening in a data set of 102 multiplex families. , 2003, American journal of human genetics.

[13]  Y. Tomer,et al.  Searching for the autoimmune thyroid disease susceptibility genes: from gene mapping to gene function. , 2003, Endocrine reviews.

[14]  S. Ho,et al.  Association of Graves' disease with intragenic polymorphism of the thyrotropin receptor gene in a cohort of Singapore patients of multi-ethnic origins. , 2003, Thyroid : official journal of the American Thyroid Association.

[15]  Y. Tomer,et al.  A germline single nucleotide polymorphism at the intracellular domain of the human thyrotropin receptor does not have a major effect on the development of Graves' disease. , 2002, Thyroid : official journal of the American Thyroid Association.

[16]  P. Green,et al.  Unusual deep intronic mutations in the COL4A5 gene cause X linked Alport syndrome , 2002, Human Genetics.

[17]  M. Krempf,et al.  Intronic mutations outside of Alu-repeat-rich domains of the LDL receptor gene are a cause of familial hypercholesterolemia , 2002, Human Genetics.

[18]  Y. Nagayama,et al.  Multiple messenger ribonucleic acid transcripts and revised gene organization of the human TSH receptor. , 2002, Endocrine journal.

[19]  W. Gauderman Sample size requirements for association studies of gene-gene interaction. , 2002, American journal of epidemiology.

[20]  S. Shirasawa,et al.  Identification of susceptibility loci for autoimmune thyroid disease to 5q31-q33 and Hashimoto's thyroiditis to 8q23-q24 by multipoint affected sib-pair linkage analysis in Japanese. , 2001, Human molecular genetics.

[21]  G. Barbesino,et al.  CTLA-4 and not CD28 is a susceptibility gene for thyroid autoantibody production. , 2001, The Journal of clinical endocrinology and metabolism.

[22]  G. Barbesino,et al.  Limited genetic susceptibility to severe Graves' ophthalmopathy: no role for CTLA-4 but evidence for an environmental etiology. , 2000, Thyroid : official journal of the American Thyroid Association.

[23]  A. Pinchera,et al.  Thyrotropin receptor polymorphisms and thyroid diseases. , 2000, The Journal of clinical endocrinology and metabolism.

[24]  D. A. Chistyakov,et al.  Complex association analysis of graves disease using a set of polymorphic markers. , 2000, Molecular genetics and metabolism.

[25]  T. Davies,et al.  New insights into the thyroid-stimulating hormone receptor. The major antigen of Graves' disease. , 2000, Endocrinology and metabolism clinics of North America.

[26]  A. Falus,et al.  Analysis of the genetic variability of the 1st (CCC/ACC, P52T) and the 10th exons (bp 1012-1704) of the TSH receptor gene in Graves' disease. , 2000, European journal of immunogenetics : official journal of the British Society for Histocompatibility and Immunogenetics.

[27]  J. Franklyn,et al.  Lack of association between polymorphism of the thyrotropin receptor gene and Graves' disease in United Kingdom and Hong Kong Chinese patients: case control and family-based studies. , 1998, Thyroid : official journal of the American Thyroid Association.

[28]  G. Barbesino,et al.  Mapping of a major susceptibility locus for Graves' disease (GD-1) to chromosome 14q31. , 1997, The Journal of clinical endocrinology and metabolism.

[29]  K. Kotsa,et al.  No association between a thyrotropin receptor gene polymorphism and Graves' disease in the female population. , 1997, Thyroid : official journal of the American Thyroid Association.

[30]  E. Milgrom,et al.  Analysis of the thyrotropin receptor as a candidate gene in familial Graves' disease. , 1996, The Journal of clinical endocrinology and metabolism.

[31]  R. Cuddihy,et al.  A polymorphism in the extracellular domain of the thyrotropin receptor is highly associated with autoimmune thyroid disease in females. , 1995, Thyroid : official journal of the American Thyroid Association.

[32]  Y. Tomer,et al.  Cloning and sequencing of a 1.3 KB variant of human thyrotropin receptor mRNA lacking the transmembrane domain. , 1992, Biochemical and biophysical research communications.

[33]  B. Rapoport,et al.  The thyrotropin receptor 25 years after its discovery: new insight after its molecular cloning. , 1992, Molecular endocrinology.

[34]  B. Rapoport,et al.  Molecular cloning, sequence and functional expression of the cDNA for the human thyrotropin receptor. , 1989, Biochemical and biophysical research communications.

[35]  W. Gilbert Why genes in pieces? , 1978, Nature.

[36]  M. Schott Interleukin (IL)-23 Receptor Is a Major Susceptibility Gene for Graves' Ophthalmopathy: The IL-23/T-helper 17 Axis Extends to Thyroid Autoimmunity , 2008 .

[37]  B. Westermark,et al.  Analysis of mutations in exon 1 of the human thyrotropin receptor gene: high frequency of the D36H and P52T polymorphic variants. , 1999, Thyroid : official journal of the American Thyroid Association.

[38]  G. Barbesino,et al.  The Journal of Clinical Endocrinology & Metabolism Printed in U.S.A. Copyright © 1999 by The Endocrine Society Mapping the Major Susceptibility Loci for Familial Graves ’ and Hashimoto’s Diseases: Evidence for Genetic , 2022 .

[39]  D. Bowden,et al.  0021-972X/05/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 90(5):2898–2903 Printed in U.S.A. Copyright © 2005 by The Endocrine Society doi: 10.1210/jc.2004-2148 Multiple SNPs in Intron 7 of Thyrotropin Receptor Are Associated with Graves ’ D , 2022 .